COMMUNIQUÉS West-GlobeNewswire

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
22/09/2025
Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s disease Alzheimer’s disease development program with positive data in successful Phase 1 and Phase [...]
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress
22/09/2025
MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract [...]
Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management
22/09/2025
Appointment strengthens Board expertise as Milestone Scientific drives commercial expansion and payer adoption of CompuFlo® in interventional pain management ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone [...]
Baylor Genetics to Showcase the Expanding Role and Clinical Value of Genetic Testing in Pediatric Neurology at the 2025 Child Neurology Society Annual Meeting
22/09/2025
Company will feature new data on genomic diagnosis in epilepsy, advocate for expanded testing access, and host a symposium on the evolving role of sequencing in patient care HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- [...]
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22/09/2025
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma [...]
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22/09/2025
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics
22/09/2025
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics Helio Diagnostics is backed by a team with 25+ years of experience in the development and manufacturing of complex diagnostic devices. Marseille, [...]
First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
22/09/2025
Research Triangle Park, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage [...]
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22/09/2025
REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the [...]
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22/09/2025
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain
22/09/2025
NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy [...]
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
22/09/2025
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney [...]
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
22/09/2025
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory [...]
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22/09/2025
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025 . The US Food and Drug Administration (FDA) has extended by three months the target [...]
L’essai de Phase II LANTIC d’Ipsen en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l’étude de Phase III
22/09/2025
L'IPN10200 est une molécule recombinante, première de sa classe (« first-in-class »), spécifiquement conçue pour obtenir une affinité et une internalisation accrues du récepteur, offrant ainsi une durée d’action [...]
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
22/09/2025
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin [...]
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
22/09/2025
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1 -mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The [...]
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
22/09/2025
Press release CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) DIJON, France – September 22, 2025 (7.30 AM CET) – CROSSJECT (ISIN: [...]
CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE®
22/09/2025
Communiqué de presse CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE® DIJON, France – 22 septembre 2025 (07H30 CET) – CROSSJECT (ISIN [...]

Pages